Evidence map›Paper›PMID 34287291›Full record

ArticleCurrent oncology (Toronto, Ont.)2021

Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice.

Joyce O'Shaughnessy, Leisha A Emens, Stephen Y Chui, Wei Wang, Kenneth Russell, Shih-Wen Lin, Carlos Flores Avile, Patricia Luhn, Andreas Schneeweiss

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Joyce O'ShaughnessyBaylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX 75251, USA.
Leisha A EmensUPMC Hillman Cancer Center, Magee-Womens Hospital, Pittsburgh, PA 15232, USA.
Stephen Y ChuiGenentech, Inc., South San Francisco, CA 94080, USA.
Wei WangPharmaceutical Outcomes and Policy, University of Florida, Gainesville, FL 32610, USA.
Kenneth RussellF. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.
Shih-Wen LinGenentech, Inc., South San Francisco, CA 94080, USA.
Carlos Flores AvileGenesis Research, Hoboken, NJ 07030, USA.ORCID 0000-0002-0574-4258
Patricia LuhnGenentech, Inc., South San Francisco, CA 94080, USA.ORCID 0000-0002-8889-0217
Andreas SchneeweissNational Center for Tumor Disease, Heidelberg University Hospital and German Cancer Research, 69120 Heidelberg, Germany.
Heidelberg University · DEMagee-Womens Hospital · USRoche (Switzerland) · CHTexas Oncology · USUniversity of Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated first-line (1L) treatment patterns and predictors of taxane use to better understand the evolving metastatic triple-negative breast cancer (mTNBC) treatment landscape. This retrospective analysis of the Truven Health MarketScan® (Somers, NY, USA) Database included women with mTNBC who received 1L therapy within six months of diagnosis (January 2005-June 2015). Multivariate logistic regression models identified predictors of taxane use, adjusting for prognostic factors. A total of 2,271 women with newly diagnosed mTNBC received 1L treatment during the study period. Half received a 1L taxane (53%), more often in combination than as monotherapy (58% versus 42%), though this varied by specific taxane.

Indexed as

Triple Negative Breast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsDocetaxelFemaleHumansRetrospective StudiesTaxoidsDocetaxelTaxoidschemotherapydocetaxelmetastatic triple-negative breast cancernab-paclitaxelpaclitaxel

Identifiers

PMID34287291
PMCPMC8293053
OpenAlexW3183886430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.